The placenta is a temporary structure unique to pregnancy functioning to sustain and protect the fetus until birth. The placenta serves as an endocrine organ producing a wide range of important signals, including many peptide hormones. Many of these peptides enter the maternal and fetal circulation and have diverse effects on the metabolic, immune and cardiovascular systems. An intricate balance of these signals is required throughout pregnancy and, in a gestational disease, this balance may be disturbed. The identification of such changes in the balance of signals may be used to detect a particular pathology or to ascertain its severity. This review considers the role and association of various placental peptide markers associated with the major gestational diseases including intrauterine growth retardation, pre-term labour, pre-eclampsia, chromosomal disorders, gestational diabetes and trophoblastic disease. Potential markers that may prove more reliable and specific in their diagnostic value and that may be used for identifying patients at risk are also discussed. The importance of the new fields of genomics and proteomics in the future discovery of new peptide markers is illustrated.

Gestational diseases
In this review, the role and association of a selection of placental peptides with regard to the major gestational diseases are considered and the discussion is confined to some of the more prominent and promising candidates.

Intrauterine growth restriction
Intrauterine growth restriction (IUGR) is defined as a predicted fetal weight for gestational age that is under the tenth percentile or < 2.5 kg. IUGR has been linked to significantly increased fetal morbidity and mortality (McCormick, 1985), with the most common causes stated as chronic hypertension, pre-eclampsia, smoking, alcohol, stress and intrauterine infections such as cytomegalovirus and rubella. These conditions are commonly cited as causing an inadequate maternal–fetal circulation.

Growth factors
Fetal growth and development are closely regulated by the paracrine and autocrine actions of various growth factors such as the insulin-like growth factors (IGF), fibroblast growth factors (FGF), epidermal growth factors (EGF), transforming growth factors (TG), and platelet-derived growth factors (PDGF). Therefore, attention has been drawn to the study of these growth factors in IUGR. The availability of these growth factors is controlled not only by gene expression, but also by proteolytic release. For example, some FGFs are stored within basement membranes and are inaccessible to target tissues without liberation by proteolysis (Herbert et al., 1990). IGF-I and IGF-II circulate in association with specific binding proteins (IGFBPs), and their bioavailability depends on the proteolysis of the specific IGFBPs.

IGF-I is believed to be the primary hormone influencing fetal growth in later gestation and is essential for placental and fetal development (Hill et al., 1998). The targeted gene deletion of the IGF-I gene in mice is shown to yield homozygotes that have a birth weight about 60% that of normal (Liu et al., 1993). During pregnancy, IGF-I concentrations parallel the increase in fetal size that occurs with advancing gestation (Bocconi et al., 1998). Thus, it is not surprising that low IGF-I concentrations correlate with infants suspected of IUGR (Lassarre et al., 1991; Ostlund et al., 1997) or that increased concentrations correlate with large-for-gestational-age fetuses (Giudice et al., 1995). There is also evidence to indicate an inverse relationship between increased IGFBP-1 concentrations at delivery and birth size (Wang et al., 1991; Holmes et al., 2000). Subsequently, the increased IGFBP-1 may be responsible for limiting the availability of IGF-I in...
the circulation observed in cases of IUGR. Nevertheless, the observed serum concentrations of IGF-I are not always reflected as differences in the amount of gene expression between normal and IUGR placentas (Abu-Amero et al., 1998). Indeed, increased expression of IGF-I in the placentas of IUGR fetuses has been proposed as a mechanism for restoring normal growth (Dalcik et al., 2001).

Protein production and release are not abnormal in all IUGR placentas but are found to be aberrant only in certain cases (Sorem and Siler-Khodr, 1998), possibly because a variety of other fetal tissues also secrete IGF-I. Leger et al. (1996) suggested that serum IGF-I concentrations are influenced by nutritional factors, leading to a wide range of individual differences in measurements and making IGF-I a potentially poor marker for IUGR.

**Leptin**

Leptin regulates body weight and homeostasis and during pregnancy is secreted in increasing amounts with gestational age, from both maternal adipose stores and the placenta (Henson and Castracane, 2000). During pregnancy, there are marked changes in leptin concentrations, which increase sharply during the first trimester and decline back to normal after delivery. It is postulated that the placenta produces these increased concentrations and that circulating leptin provides a growth-promoting signal for fetal development during late pregnancy. Indeed, serum leptin concentrations are significantly lower in new-born babies with IUGR than those in the maternal circulation (Jaquet et al., 1998). Fetal leptin concentrations show good correlation with fetal growth, and leptin concentrations in IUGR fetuses are lower than in controls (Varvarigou et al., 1999), except in cases of severe IUGR in which increased leptin concentrations may be associated with fetal distress (Cetin et al., 2000). In contrast, maternal and placental leptin concentrations are increased in pregnancies associated with IUGR (Lepercq et al., 2001). Umbilical cord leptin concentrations appear to be independent of placental leptin concentrations and hence may be a marker of fat mass in fetuses (Lepercq et al., 2001). It is clear that the site of serum sampling, from either the mother or fetus, is important in determining the diagnostic value of leptin.

**Vasoactive peptides**

During pregnancy, extensive haemostatic changes occur in the utero–placental circulation and, in pregnancies complicated by IUGR, a restricted physiological adaptation of the utero–placental blood vessels leads to increased vascular resistance and reduced blood flow. Therefore, candidate markers can be extended to any peptide involved in the control of the utero–placental blood flow and many peptides implicated in causing hypertension are also believed to be responsible for reducing the utero–placental blood circulation. Endothelin (ET-1), a potent vasoconstrictor originally discovered secreted from the endothelium has been implicated in IUGR (Harvey-Wilkes et al., 1996), occurring in increased concentrations in IUGR-associated pregnancy-induced hypertension (Di Iorio et al., 1996). However, in ten IUGR pregnancies not complicated by hypertension, decreased concentrations of endothelin were observed (Heffner et al., 1999). Other potential markers include angiotensin II (part of the renin–angiotensin system responsible for controlling blood pressure, electrolyte homeostasis and volume regulation), which occurs in increased concentrations in cases of IUGR (Kingdom et al., 1993), and proinflammatory cytokines such as TNF-α, of which there is increased production in cases of IUGR (Holcberg et al., 2001). These factors also enhance the vasoconstriction of the placental bed, thus reducing blood flow. Vasoactive peptides are discussed further in the section on pre-eclampsia.
Pre-term labour

The regulatory pathways leading to parturition in humans are not well defined compared with this process in other mammals. As a result, the number of pre-term births has not fallen over the past 30 years, although advances in neonatal care have resulted in a significant increase in successful outcomes. Major economic costs are associated with caring for pre-term neonates and there is epidemiological evidence of increased risk of disease in later life in these individuals (Barker, 1989).

Corticotrophin releasing factor

Many factors are involved in human parturition, including the interleukins, the endothelins, oxytocin, urocortin and various steroid hormones. Much of the recent and prominent interest in this area has been focussed on corticotrophin releasing factor (CRF), which is released by the placenta during pregnancy in exponentially increasing amounts (Campbell et al., 1987). Until approximately 3 weeks before parturition, the biological activity of this placental peptide is masked by a specific binding protein CRF-BP (Linton et al., 1993; McLean et al., 1995). After this point, the concentrations of CRF exceed those of the CRF-BP, resulting in a sudden increase in the concentrations of bio-available CRF (McLean et al., 1995). It may be this increase that initiates the positive feedback loops that result in parturition (McLean and Smith, 1999).

Many studies have shown that in pregnancies resulting in pre-term birth, the concentrations of CRF in maternal plasma are significantly higher at every stage (Fig. 2a) than those in pregnancies that proceed to full term (McLean et al., 1995). Correspondingly, plasma CRF concentrations are lower in women who deliver post-term. There is some evidence that concentrations of the CRF-BP are correspondingly lower in pre-term than in normal term pregnancies (Hobel et al., 1999). However, these lower concentrations of CRF-BP could be the result of increased clearance of the CRF-CRF-BP complex (Woods et al., 1994), rather than any alteration in the expression of CRF-BP. Although some groups of investigators have reported no differences between normal and pre-term concentrations of CRF, it is generally considered that these findings are the result of interference of the CRF-BP with some CRF assays (Linton et al., 1995). As a result, the concentration of maternal plasma CRF is perhaps the most reliable indicator of patients at risk from pre-term labour. In combination with plasma CRF-BP and alpha-fetoprotein measurements, such patients can be identified as early as the second trimester (McLean et al., 1999).

Pre-eclampsia

Pre-eclampsia is a principal cause of maternal morbidity and mortality, and occurs in 3–10% of pregnancies worldwide. The mild form commonly presents with maternal hypertension and proteinuria, but can swiftly and unpredictably become severe with many extensive complications, involving the maternal liver, kidneys, lungs, blood vessels and nervous system. These clinical problems only become apparent in the second half of pregnancy but are believed to start during the first trimester. It is thought that defective trophoblastic invasion of the placental bed results in hypoperfusion and an ischaemic placenta, with the release of unknown factors, which pre-date the condition, into the maternal circulation.

Vasoactive peptides

The most commonly reported symptom in pre-eclampsia is hypertension and it is not surprising that attention has
focussed predominantly on the powerful vasoconstrictors. In addition, peptides that may be able to compensate for the hypertensive effects of these by regulating the blood flow to the utero-placental unit have received attention. Of the vasoconstrictors, the endothelins and angiotensins, which help control the functions of vascular smooth muscle cells and circulating blood cells, have received most attention. ET-1 concentrations are significantly higher in the placent al tissues of women with pre-eclampsia (Singh et al., 2001) and, as a consequence, in plasma too (Rust et al., 1997). However, first trimester plasma endothelin concentrations need to be combined with mid-trimester blood pressure readings to increase the predictive value from 55.5 to 68.2% (Shaarawy and Abdel-Magid, 2000). Similarly, increased concentrations of angiotensin I and decreased concentrations of angiotensin II in the first week after birth are possible indicators of why some women with pre-eclampsia are more prone to deteriorate during this period. (Zunker et al., 1998). Neuropeptide Y, an abundant and widespread peptide in the nervous system, is another potent vasoconstrictor that has been implicated in pre-eclampsia. Although increased plasma concentrations of neuropeptide Y have been reported in women with pre-eclampsia (Khatun et al., 2000), other studies have reported no correlation (Egerman et al., 1999). The vasodilators reported as potential markers in pre-eclampsia include atrial natriuretic factor, normally implicated in the control of extracellular fluid volume and electrolyte homeostasis (Zhao, 1993), and vasoactive intestinal polypeptide, normally a neurotransmitter exhibiting a wide variety of biological actions (Holst et al., 1991). Both of these peptides are shown to be higher in women with pre-eclampsia, whereas adrenomedullin, a peptide that elicits long-lasting vasodilation, has been reported both to decrease (Hata et al., 1997) and to increase (Di Iorio et al., 1998) in pre-eclampsia in different groups of patients.

Preliminary evidence also indicates that neurokinin B (NKB), previously never found in the periphery, fulfils the criteria for a specific pre-eclampsia marker (Page et al., 2000a). NKB is a member of the tachykinins, peptides that were originally identified as neurotransmitters. NKB has been found to cause the potent contraction of the hepatic portal vein, venoconstriction of the mesenteric beds and the increase in heart rate seen in pre-eclampsia (Page et al., 2000a). NKB is present in high concentrations in the plasma of women with pre-eclampsia and is low or undetectable in most normotensive pregnancies (Fig. 2b) and completely absent in the plasma of men and non-pregnant women (Page et al., 2000a). Placental NKB has several advantages over other candidate markers for pre-eclampsia as it appears unique not only to pre-eclampsia but also to pregnancy, and is not associated with other known hypertensive disorders. NKB secretion may start as early as week 9 of pregnancy as a compensatory mechanism to ensure an adequate blood supply to the fetus. As a result, NKB may be the single most effective predictive marker, detecting women at risk from pre-eclampsia as early as the first trimester.

Leptin, β-human chorionic gonadotrophin (β-hCG) and inhibin are perhaps the most studied of the non-vasoactive markers for pre-eclampsia.

Maternal plasma leptin increases in gestational hypertension and pre-eclampsia (Vitoratos et al., 2001). Leptin may be predictive of pre-eclampsia, as one study demonstrates the increase of maternal plasma leptin before the clinical onset of pre-eclampsia (Anim-Nyame et al., 2000), although Martinez-Abundis et al. (2000) report that serum leptin concentrations are similar in patients with different grades of pre-eclampsia and normotensive pregnancies.

In the case of β-hCG, there are several reports of an association with the incidence of pre-eclampsia. hCG is secreted from the blastocyst and early placenta and prolongs the life of the corpus luteum. The detection of hCG secretion is used as the basis for the pregnancy test, the most clear-cut and diagnostic test involving a peptide marker during pregnancy. Vaillant et al. (1996) found hCG concentrations at 17 weeks to be a positive predictor for pre-eclampsia comparable to the best and earliest testing method for pre-eclampsia, namely the abnormalities of the Doppler waveforms of the uterine arteries. Ashour et al. (1997) found increased concentrations in the second trimester, but this association was only significant among multiparous women. Only when hCG was incorporated into a multifactorial model (including body mass index, parity and age) did the sensitivity of the test prove effective with a specificity of 71% (Lee et al., 2000).

The inhibins are gonadal glycoproteins that normally regulate pituitary FSH, whereas the related activins are peptides that act as growth and differentiation factors in many cells and tissues. In maternal serum, concentrations of inhibin A are found to be eight times higher and activin A concentrations nine times higher in pre-eclampsia than in controls (Muttukrishna et al., 1997). Very little overlap in inhibin A and activin A concentrations are observed between women with pre-eclampsia and controls, indicating that they both could be very sensitive markers for pre-eclampsia.

Chromosomal disorders

Another major area in which pre-natal screening is important is chromosomal disorders. Large genomic changes, such as aneuploidy (differences in the number of chromosomes), deletions and other chromosomal rearrangements, have long been associated with pregnancy loss, congenital abnormalities and malignancy. Chromosome disorders are typically the result of errors of recombination at meiosis, and so their occurrence cannot often be predicted before fertilization, although certain risk factors, such as maternal age, might indicate that screening is appropriate. Perhaps the most well known chromosomal disorder is Down syndrome resulting from an extra copy (trisomy) of chromosome 21. Other examples include Patau syndrome (trisomy 13), Edwards syndrome (trisomy 18), Turner syndrome (X0),...
Leptin and growth factors

Other markers

EGF expression is higher in molar placentas (in which the trophoblast implants normally but exhibits abnormal proliferation) of all gestational ages, linking its role to the proliferative and differentiating activity of the trophoblast.

Trophoblastic disease

The reported incidence of GTD varies and is an order of magnitude higher in Nigeria than it is in the United States (Elegebe et al., 1984). Although the patterns of hCG secretion are similar in both populations during normal pregnancy, the concentration of the alpha subunit of hCG is persistently higher in Nigerian women than in comparable pregnant American women. The higher concentration of the alpha subunit during pregnancy in Nigeria may be a marker indicating a population of women at higher risk for developing the malignancy (Elegebe et al., 1984). GTTs are always histologically choriocarcinomas and secrete the beta-subunit of hCG more abundantly than normal. The serum or urinary concentration of this subunit is found to be proportional to the tumour volume and represents a very good fundamental basis for assessing the need for follow-up treatment for these tumours (Ngan and Wong, 1999).
Tumours resulting in histological diagnosis of invasive moles and choriocarcinomas show very strong binding of EGF and so EGF is believed to have the potential of identifying high-risk lesions (John et al., 1997). Fan et al. (1999) demonstrated that diagnosis of malignant trophoblastic tumours can be made with an accuracy of 91.3% by detecting early pregnancy factor-like activity, and that this activity could also be used as an indicator to distinguish benign from malignant trophoblastic tumours.

**Future discovery of placental peptide markers**

To date, most peptide markers used clinically have been identified using classical approaches such as chromatography and immunoassay. This is certainly true of the markers of the popular triple test for Down syndrome. Unfortunately, such tests have inherently low accuracies and the need for improvement has led to the inclusion of additional markers. The search for ideal markers in diagnosis and screening continues and as all peptides are encoded by the genome it is possible to use molecular and bio-informatic approaches to trawl the genome for more efficient markers (Fig. 3).

Differential display, which compares and identifies genes expressed at different time points or in different pathologies, can be used to identify new peptides expressed by the placenta (Page et al., 2000b). Although effective in revealing new genes, differential display is time consuming, as the partial gene fragments generated have to be cloned,
Placental peptides as markers of gestational disease

sequence and reconstructed. Only 7.5% of the differentially expressed genes we have used encode secreted proteins and hence have any potential as new gestational markers (Page et al., 2000b). Differential display is now being superseded by biochip and microarray systems (for a review, see Jain, 2000), formed either by the synthesis of oligonucleotides or the spotting of DNA fragments onto the surface of glass chips; the latest chips have about a million probe sequences. Hybridization of fluorescenced tagged RNA or complementary DNA probes from placentas with different pathologies allows the monitoring of mRNA expression. DNA sequences are identified accurately by a scanning device that detects the fluorescent signals produced by the hybridized probes, and identifies differences in probe binding. Since the sequence of the spotted DNA fragments on the biochips is already known, genes do not have to be cloned and sequenced to obtain additional gene information. The application of proteomics is just as important (for a review, see Palfreyman, 1998). Peptide expression can also be controlled after transcription and important details not observed by differential display may be revealed. Hence, advances in high throughput two-dimensional gel electrophoresis and mass spectrometry have added to understanding of the patterns of peptide and protein expression, for example, expression profiles can be attained from extracted placental and serum samples. Bioinformatics (the integration of biology and computer science) has become one of the fastest growing fields in biological research (for a review, see Luscombe et al., 2001). The momentum of the Human Genome Project has provided the opportunity to gather and store vast arrays of valuable data. These databases can be explored with keywords as simple as ‘placenta’ or sequence motifs of peptides to identify partial and uncharacterized cDNA sequences such as expressed sequence tags or tentative human consensus sequences (for a review, see Boguski, 1995). 5’ and 3’ rapid amplification of cDNA ends of candidate placental genes can then be performed to reveal the full-length cDNA sequence of each respective gene. The cDNA can be subsequently translated and analysed by computer programs to reveal and confirm secretory and peptide motifs. The armoury of tools to assist in the identification of new placental peptide precursors and their peptide components has never been greater.

Conclusion

Many of the tests used currently for gestational disease provide only an estimation of risk and therefore it is vital to develop new prenatal screening tests that are more reliable and specific. A case for early first trimester diagnosis is emerging to help reduce the psychological anxiety and pathological trauma faced by prospective parents. Peptide markers may be able to fill this niche, although ideally they should be unique to the condition and specific to a stage of the disease. It is clear that although peptides are very promising candidates, there remains much to be learnt. Not all peptide markers are unique to any one particular condition and there are few large longitudinal studies to guide the use of placental markers in clinics. Consequently, we are left with many reports of different associations of a peptide with a particular disease. Different studies raise, lower or leave unchanged concentrations of a prospective marker, leaving its predictive value questionable. It is perhaps more important to define the root cause of a particular gestational disease. For example, IUGR appears multifactorial, and sometimes the cause might be another gestational disease such as pre-eclampsia. If IUGR occurs concurrently with pre-eclampsia, is it a consequence of pre-eclampsia or did it arise independently? Should it be markers for IUGR or pre-eclampsia that are chosen? In addition, would the same profile of peptides be expected to be displayed if IUGR arises from maternal diabetes, as opposed to from an infection such as cytomegalovirus?

In conclusion, prenatal screening is an important and routine part of modern obstetric care and the demand for developing new ultimate novel diagnostic markers remains challenging.

The authors would like to thank Sophie Neville, Selma Omer and Nicola Bell for their assistance and help in the preparation of this manuscript.

References

Key references are identified by asterisks.


Arany E and Hill DJ (1998) Fibroblast growth factor-2 and fibroblast growth factor receptor-1 mRNA expression and peptide localization in placenta from normal and diabetic pregnancies Placenta 19 133–142


Bocconi L, Mauro F, Maddalena SE, De Iulio C, Tirelli AS, Pace E and Nicolini U (1998) Insulin-like growth factor 1 in controls and growth-retarded fetuses Fetal Diagnosis and Therapy 13 192–196


Cetin I, Morpurgo PS, Radaelli T, Taricone E, Cortelazzi D, Bellotti M, Pardi G and Berk-Peccoz P (2000) Fetal plasma leptin concentrations: relationship with different intrauterine growth patterns from 19 weeks to term Pediatric Research 28 646–651


Downloaded from Bioscientifica.com at 08/22/2019 04:35:51PM via free access


